1. Combination Versus Monotherapy for Carbapenem-Resistant Acinetobacter Species Serious Infections: A Prospective IPTW Adjusted Cohort Study
- Author
-
Abi Manesh, Mithun Mohan George, Prasannakumar Palanikumar, V. Nagaraj, Kundakarla Bhanuprasad, Ramya Krishnan, G. Nivetha, Binesh Lal, K. Rajitha Triveni, Priyanka Gautam, Biju George, Uday Kulkarni, Vikram Mathews, K. Subramani, Shoma Rao, Binila Chacko, Anand Zachariah, Sowmya Sathyendra, Samuel George Hansdak, Ooriapadickal Cherian Abraham, Ramya Iyadurai, Rajiv Karthik, John Victor Peter, Yin Mo, Balaji Veeraraghavan, George M. Varghese, and David Leslie Paterson
- Subjects
Acinetobacter ,Combination therapy ,CRAB infections ,Polymyxins ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction International guidelines recommend definitive combination antibiotic therapy for the management of serious infections involving carbapenem-resistant Acinetobacter (CRAB) species. The commonly available combination options include high-dose sulbactam, polymyxins, tetracyclines, and cefiderocol. Scanty prospective data exist to support this approach. Methods Patients with CRAB bacteraemia, ventilator-associated pneumonia (VAP), or both were categorized based on whether they received combination therapy or monotherapy. The 30-day mortality was compared between the two groups. Inverse probability treatment weighting (IPTW) was done using propensity score (PS) for a balanced comparison between groups. Results Between January 2021 and May 2023, of the 161 patients with CRAB bacteraemia (n = 55, 34.2%), VAP (n = 46, 28.6%), or both (n = 60, 37.3%) who received appropriate intravenous antibiotic therapy, 70% (112/161) received monotherapy, and the rest received combination therapy. The overall 30-day mortality was 62% (99/161) and not different (p = 0.76) between the combination therapy (31/49, 63.3%) and monotherapy (68/112, 60.7%) groups. The propensity score matching using IPTW did not show a statistical difference (p = 0.47) in 30-day mortality for receiving combination therapy with an adjusted odds ratio (OR) P of 1.29 (0.64, 2.58). Conclusion Combination therapy for CRAB infections needs further study in a randomised controlled trial, as this observational study showed no difference in 30-day mortality between monotherapy and combination therapy.
- Published
- 2024
- Full Text
- View/download PDF